Suppression of T cell activation by hirsutenone, isolated from the bark of Alnus japonica, and its therapeutic advantages for atopic dermatitis

European Journal of Pharmacology

Volumn 614, Issue 1-3, 2009, Pages 98-105

  Joo, Seong Soo ^a   Kim, Sung Geun ^b   Choi, Sun Eun ^b   Kim, Yun Bae ^a   Park, Hee Yong ^b   Seo, Seong Jun ^b   Choi, Young Wook ^b   Lee, Min Won ^b   Lee, Do Ik ^b  

^a Chungbuk National University   (South Korea)

^b Chung Ang University   (South Korea)

Author keywords

hexosaminidase; Atopic dermatitis; Calcineurin inhibitor; Hirsutenone; T lymphocyte

Indexed keywords

CALCIUM; CYCLOSPORIN A; CYTOKINE; DERMATOLOGICAL AGENT; GAMMA INTERFERON; HIRSUTENONE; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 5; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

ALDER; ALNUS JAPONICA; ANIMAL CELL; ARTICLE; ATOPIC DERMATITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ISOLATION; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INACTIVATION; ENZYME INHIBITION; MAST CELL DEGRANULATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; SPLEEN CELL; T LYMPHOCYTE ACTIVATION;

ALNUS; ANIMALS; ANTIBODIES; ANTIGENS, CD3; BETA-N-ACETYLHEXOSAMINIDASES; BIOLOGICAL MARKERS; BIOMIMETICS; CALCINEURIN; CATECHOLS; CELL PROLIFERATION; CYTOKINES; DERMATITIS, ATOPIC; DIARYLHEPTANOIDS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE ACTIVATION; MAST CELLS; MICE; NFATC TRANSCRIPTION FACTORS; PLANT BARK; RNA, MESSENGER; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TH1 CELLS; TH2 CELLS;

EID: 67349270085     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.04.047     Document Type: Article

References (31)

1. Akdis A.C., Akdis M., Trautmann A., and Blaser K. Immune regulation in atopic dermatitis. Curr. Opin. Immunol. 12 (2002) 641-646
2. Alomar A., Berth-Jones J., Bos J.D., Giannetti A., Reitamo S., Ruzika T., Stalder J.-F., and Thestrup-pedersen K. The role of topical calcineurin inhibitors in atopic dermatitis. Brit. J. Dermatol. 151 (2004) S3-27
3. Back O., Scheynius A., and Johansson S.G.O. Ketoconazole in atopic dermatitis: therapeutic response in correlated with decrease in serum IgE. Arch. Dematol. Res. 287 (1995) 448-451
4. Bornhove E.C., Burgdorf W.H., and Wollenberg A. Immunomodulatory macrolactams for topical treatment of inflammatory skin diseases. Curr. Opin. Investig. Drugs 3 (2002) 708-712
5. Breuer K., Werfel T., and Kapp A. Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. Am. J. Clin. Dermatol. 6 (2005) 65-77
6. Chapman M.S., Schachner L.A., Breneman D., Boguniewicz M., Gold M.H., Shull T., Linowski G.J., and Jaracz E. Tacrolimus ointment 0.03% shows efficacy and safety in pediatric and adult patients with mild to moderate atopic dermatitis. J. Am. Acad. Dermatol. 53 (2005) S177-815
7. Cohen J.S., and Brown H.A. Phospholypases stimulates secretion in RBL mast cells. Biochemistry 40 (2001) 6589-6597
8. De Rie M.A., Meinardi M.M., and Bos J.D. Lack of efficacy of topical cyclosporine A in atopic dermatitis and allergic contact dermatitis. Acta Derm. Venereol. 71 (1991) 452-454
9. Dong C., Davis R.J., and Flavell R.A. MAP kinases in the immune response. Annu. Rev. Immunol. 20 (2002) 55-72
10. Ellison J.A., Patel L., Ray D.W., David T.J., and Clayton P.E. Hypothalamicpituiary-a drenal function and glucocorticoid sensitivity in atopic dermatitis. Pediatrics 105 (2000) 794-799
11. Freund Y.R., Dousman L., MacGregor J.T., and Mohagheghpour N. Oral treatment with timrthoprim-sulfamethoxazole and zidovudine suppresses murin accessory cell-dependent immune response. Toxicol. Sci. 55 (2000) 335-342
12. Hardie R.A., Waring A.J., and Barnetson R.S. Atrophic skin striae following the use of clobetasol propionate ointment. Practitioner 219 (1977) 376-378
13. Heinzel F.P., Sadick M.D., Holaday B.J., Coffman R.L., and Locksley R.M. Reciprocal expression of interferon-γ or IL-4 during the resolution or progression of murine leishmaniasis: evidence for expression of distinct helper T cell subset. J. Exp. Med. 169 (1989) 59-72
14. Hussain I., and Kline J.N. DNA, the immune system, and atopic disease. J. Investig. Dermatol. Symp. Proc. 9 (2004) 23-28
15. Kang S., Lucky A.W., Pariser D., Lawrence I., and Hanifin J.M. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J. Am. Acad. Dermatol. 44 (2001) S58-64
16. Kim H.J., Kim K.H., Yeom S.H., Kim M.K., Shim J.G., Lim H.W., and Lee M.W. New Diarylheptanoids from the barks of Alnus japonica Steudel. Chin. Chem. Lett. 16 (2005) 1337-1340
17. Kuhn D.M., Balkis M., Chandra J., Mukherjee P.K., and Ghannoum M.A. Uses and limitations of the XTT assay in studies of Candida growth and metabolism. J. Clin. Microbiol. 41 (2003) 506-508
18. Leung D.Y. Atopic dermatitis: the skin as a window into the pathogenesis of chronic allergic disease. J. Allergy Clin. Immunol. 96 (1995) 302-318
19. Leung D.Y.M., Boguniewicz M., Howell M.D., Nomura I., and Hamid Q.A. New insight into atopic dermatitis. J. Clin. Invest. 113 (2004) 651-657
20. Levy M.L. Atopic dermatitis: understanding the disease and its management. Curr. Med. Res. Opin. 23 (2007) 3091-3103
21. Luger T.A., Lahfa M., Folster-Holst R., Gulliver W.P., Allen R., Molloy S., Barbier N., Paul C., and Bos J.D. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J. Derm. Treat. 15 (2004) 169-178
22. Meingassner J.G., Aschauer H., Stuetz A., and Billich A. Pimecrolimus permeates less than tacrolimus through normal, inflamed, or corticosteroid-pretreated skin. Exp. Dermatol. 14 (2005) 752-757
23. Nghiem P., Pearson G., and Langly R.G. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J. Am. Acad. Dermatol. 46 (2002) 228-241
24. Oikarinen A., and Autio P. New aspects of the mechanism of corticosteroid-induced dermal atrophy. Clin. Exp. Dermatol. 16 (1991) 416-419
25. Reitamo S., and Remitz A. Topical immunomodulators in the treatment of atopic eczema. In: Ring J., Przybilla B., and Ruzicka T. (Eds). Handbook of Atopic Eczema. second ed. (2006), Springer, Berlin 571-575
26. Rincon M., Flavell R.A., and Davis R.J. Signal transduction by MAP kinases in T lymphocytes. Oncogene 20 (2001) 2490-2497
27. Sharma S., Chopra K., Kulkarni S.K., and Agrewala J.N. Resveratrol and curcumin suppress immune response through CD28/CTLA-4 and CD80 co-stimulatory pathway. Clin. Exp. Immunol. 147 (2007) 155-163
28. Spergel J.M., and Paller A.S. Atopic dermatitis and the atopic march. J. Allergy Clin. Immunol. 12 (2003) S118-127
29. Thaci D. Long term management of childhood atopic dermatitis with calcineurin inhibitors. Hautarz 54 (2003) 418-423
30. Wollenberg A., Reitamo S., Atzori F., Lahfa M., Ruzicka T., Healy E., Giannetti A., Bieber T., Vyas J., and Deleuran M. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy 63 (2008) 742-750
31. Zhou B., Cron R.Q., Wu B., Genin A., Wang Z., Liu S., Robson P., and Baldwin H.S. Regulation of the Murine Nfatc1 Gene by NFATc2. J. Biol. Chem. 277 (2002) 10704-10711